Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$2.28 USD

2.28
7,179,830

+0.17 (8.06%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $2.26 -0.02 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

Zacks Equity Research

bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona

by Zacks Equity Research

bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.

Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -61% and 67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View

by Zacks Equity Research

Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.

Zacks Equity Research

Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Zacks Equity Research

Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down

by Zacks Equity Research

Bausch (BHC) declines as it misses on earnings and sales in the first quarter.

Zacks Equity Research

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

Zacks Equity Research

Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.

Zacks Equity Research

Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%

by Zacks Equity Research

Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine

Zacks Equity Research

Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.